AU2003251739A1 - New neuropeptide y y5 receptor antagonists - Google Patents

New neuropeptide y y5 receptor antagonists

Info

Publication number
AU2003251739A1
AU2003251739A1 AU2003251739A AU2003251739A AU2003251739A1 AU 2003251739 A1 AU2003251739 A1 AU 2003251739A1 AU 2003251739 A AU2003251739 A AU 2003251739A AU 2003251739 A AU2003251739 A AU 2003251739A AU 2003251739 A1 AU2003251739 A1 AU 2003251739A1
Authority
AU
Australia
Prior art keywords
receptor antagonists
neuropeptide
new
new neuropeptide
antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003251739A
Other languages
English (en)
Other versions
AU2003251739A8 (en
Inventor
Andrew W. Stamford
Yusheng Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of AU2003251739A8 publication Critical patent/AU2003251739A8/xx
Publication of AU2003251739A1 publication Critical patent/AU2003251739A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2003251739A 2002-07-02 2003-06-30 New neuropeptide y y5 receptor antagonists Abandoned AU2003251739A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39332702P 2002-07-02 2002-07-02
US60/393,327 2002-07-02
PCT/US2003/020489 WO2004005262A2 (en) 2002-07-02 2003-06-30 New neuropeptide y y5 receptor antagonists

Publications (2)

Publication Number Publication Date
AU2003251739A8 AU2003251739A8 (en) 2004-01-23
AU2003251739A1 true AU2003251739A1 (en) 2004-01-23

Family

ID=30115567

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003251739A Abandoned AU2003251739A1 (en) 2002-07-02 2003-06-30 New neuropeptide y y5 receptor antagonists

Country Status (8)

Country Link
US (1) US7157472B2 (enExample)
EP (1) EP1601666A2 (enExample)
JP (1) JP4498133B2 (enExample)
CN (1) CN1678608A (enExample)
AU (1) AU2003251739A1 (enExample)
CA (1) CA2490470A1 (enExample)
MX (1) MXPA05000200A (enExample)
WO (1) WO2004005262A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010008700A (es) * 2008-02-22 2010-08-30 Hoffmann La Roche Moduladores de beta-amiloide.
AU2009301210B2 (en) * 2008-10-09 2014-05-15 F. Hoffmann-La Roche Ag Modulators for amyloid beta
CN102209537A (zh) * 2008-11-10 2011-10-05 弗·哈夫曼-拉罗切有限公司 杂环γ分泌酶调节剂
US20110190269A1 (en) * 2010-02-01 2011-08-04 Karlheinz Baumann Gamma secretase modulators
US8486967B2 (en) 2010-02-17 2013-07-16 Hoffmann-La Roche Inc. Heteroaryl substituted piperidines
SG10201913053QA (en) 2011-05-13 2020-03-30 Array Biopharma Inc Pyrrolidinyl urea and pyrrolidinyl thiourea compounds as trka kinase inhibitors
US9981959B2 (en) 2012-11-13 2018-05-29 Array Biopharma Inc. Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
WO2014078331A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. N-(arylalkyl)-n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
WO2014078325A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. N-(monocyclic aryl),n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
WO2014078408A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
US9828360B2 (en) 2012-11-13 2017-11-28 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
US9809578B2 (en) 2012-11-13 2017-11-07 Array Biopharma Inc. Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trkA kinase inhibitors
WO2014078328A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. N-bicyclic aryl,n'-pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
RS55593B1 (sr) 2012-11-13 2017-06-30 Array Biopharma Inc Jedinjenja biciklične uree, tiouree, guanidina i cijanoguanidina korisna za lečenje bola
SMT201800169T1 (it) 2012-11-13 2018-05-02 Array Biopharma Inc Composti di n-pirrolidinile, n'-pirazolile-urea, tiourea, guanidina e cianoguanidina come inibitore di chinasi trka
WO2014078372A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
WO2015084936A1 (en) * 2013-12-04 2015-06-11 The Scripps Research Institute Novel compounds as jnk kinase inhibitors
WO2015089800A1 (en) 2013-12-19 2015-06-25 Eli Lilly And Company Fluorophenyl pyrazol compounds
EP3154959B1 (en) 2014-05-15 2019-07-10 Array Biopharma, Inc. 1-((3s,4r)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methylpyrimidin-5-yl)-1-phenyl-1h-pyrazol-5-yl)urea as a trka kinase inhibitor
KR101689382B1 (ko) 2015-05-11 2016-12-23 코오롱인더스트리 주식회사 이동통신단말 착신 알림 기능을 구비한 스마트 백 및 이를 활용한 착신 알림 방법
CN107849035B (zh) * 2015-12-29 2021-12-10 四川海思科制药有限公司 一种苯基杂环衍生物及其在医药上的用途
EP3976635A4 (en) * 2019-05-30 2023-06-28 The Regents Of The University Of California Methods of treating hyperlipidemia conditions with netrin-1 compounds

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2928485A1 (de) 1979-07-14 1981-01-29 Bayer Ag Verwendung von harnstoffderivaten als arzneimittel bei der behandlung von fettstoffwechselstoerungen
NZ201395A (en) * 1981-07-30 1987-02-20 Bayer Ag Pharmaceutical compositions containing 1,4-dihydropyridines and certain of these dihydropyridines
US4616014A (en) * 1981-10-22 1986-10-07 Fujisawa Pharmaceutical Co., Ltd. Triazine derivatives, and pharmaceutical compositions comprising the same
US4623662A (en) 1985-05-23 1986-11-18 American Cyanamid Company Antiatherosclerotic ureas and thioureas
DE3601196A1 (de) * 1986-01-17 1987-07-23 Merck Patent Gmbh 1,4-dihydropyridine
FI95572C (fi) * 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
DE3810848A1 (de) 1988-03-30 1989-10-19 Boehringer Ingelheim Kg Neue 2,3,4-substituierte imidazole und 3,4,5-substituierte 1,2,4-triazole, ihre herstellung und verwendung
EP0457803A4 (en) 1989-02-08 1991-12-04 Abbott Laboratories 4-hydroxythiazoles as 5-lipoxygenase inhibitors
DE4023215A1 (de) * 1990-07-21 1992-01-23 Hoechst Ag Substituierte azole, verfahren zu deren herstellung, sie enthaltende mittel und deren verwendung
JPH0841006A (ja) 1994-08-05 1996-02-13 Nisshin Flour Milling Co Ltd ジウレア誘導体
US5602024A (en) 1994-12-02 1997-02-11 Synaptic Pharmaceutical Corporation DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5) and uses thereof
PT885215E (pt) 1996-02-13 2006-08-31 Abbott Lab Novos derivados de pirrolidina substituidos com benzo-1,3-dioxolilo e benzofuranilo como antagonistas de endotelina
US5792138A (en) 1996-02-22 1998-08-11 Apollo Camera, Llc Cordless bipolar electrocautery unit with automatic power control
DE69720051T2 (de) * 1996-12-03 2003-09-04 Banyu Pharmaceutical Co., Ltd. Harnstoffderivate
EP0945439B1 (en) * 1996-12-13 2003-03-19 Banyu Pharmaceutical Co., Ltd. Aminopyrazole derivatives
EP1001764A4 (en) 1997-05-29 2005-08-24 Merck & Co Inc HETEROCYCLIC AMIDE COMPOUNDS AS INHIBITORS OF CELL ADHESION
US6329395B1 (en) * 1998-06-08 2001-12-11 Schering Corporation Neuropeptide Y5 receptor antagonists
DE69929235T2 (de) 1998-11-10 2006-08-24 Merck & Co., Inc. Spiro-indole als y5-rezeptor antagonisten
US6291476B1 (en) * 1999-05-12 2001-09-18 Ortho-Mcneil Pharmaceutical, Inc. Pyrazole carboxamides useful for the treatment of obesity and other disorders
TWI279402B (en) * 1999-08-20 2007-04-21 Banyu Pharma Co Ltd Spiro compounds having NPY antagonistic activities and agents containing the same
JP3411262B2 (ja) * 1999-08-20 2003-05-26 萬有製薬株式会社 新規スピロ化合物
US20030022891A1 (en) * 2000-12-01 2003-01-30 Anandan Palani MCH antagonists and their use in the treatment of obesity
WO2002049648A1 (en) 2000-12-21 2002-06-27 Schering Corporation Heteroaryl urea neuropeptide y y5 receptor antagonists
DE60235114D1 (de) * 2001-11-01 2010-03-04 Icagen Inc Pyrazolamide zur anwendung in der behandlung von schmerz

Also Published As

Publication number Publication date
US7157472B2 (en) 2007-01-02
CN1678608A (zh) 2005-10-05
US20040034008A1 (en) 2004-02-19
MXPA05000200A (es) 2005-06-06
WO2004005262A3 (en) 2004-04-15
AU2003251739A8 (en) 2004-01-23
WO2004005262A2 (en) 2004-01-15
CA2490470A1 (en) 2004-01-15
JP4498133B2 (ja) 2010-07-07
JP2005532392A (ja) 2005-10-27
EP1601666A2 (en) 2005-12-07
WO2004005262A8 (en) 2005-04-28

Similar Documents

Publication Publication Date Title
AU2003251739A1 (en) New neuropeptide y y5 receptor antagonists
AU2001294547A1 (en) Substituted urea neuropeptide y y5 receptor antagonists
AU2003241836A1 (en) Lpa receptor antagonists
AU2003261392A1 (en) M3muscarinic acetylcholine receptor antagonists
IL159643A0 (en) Substituted urea neuropeptide y y5 receptor antagonists
IL165841A0 (en) Mchir antagonists
AU2003299807A1 (en) Heteroarylalkanoic acids as integrin receptor antagonists
AUPR833401A0 (en) G protein-coupled receptor antagonists
AU2002234056A1 (en) Heteroaryl urea neuropeptide Y Y5 receptor antagonists
AU2003231513A1 (en) Pgd2 receptor antagonist
AU2002341834A1 (en) Antagonists
IL174538A0 (en) Thrombin receptor antagonists
AU2002367424A1 (en) Androgen receptor antagonists
AU2003255501A1 (en) Cxcr4 receptor antagonists
AU2003291959A1 (en) Novel glucagon antagonists
IL165727A0 (en) Chemokine antagonists
AU2003260072A1 (en) Antagonists of chemokine receptors
AU2003267088A1 (en) Chemokine receptor antagonists as therapeutic agents
AU2003236247A1 (en) Bombesin antagonists
AU2003240705A1 (en) Morpholinylmethylureas ccr-3 receptor antagonists
AU2003206014A1 (en) Neuropeptide receptor and uses thereof
AU2002359524A1 (en) P2x7 receptor antagonists
GB0101223D0 (en) Histamine receptor antagonists
IL162534A0 (en) Novel alkansulfonamides as endotheline antagonists
HK1076470A (en) New neuropeptide y y5 receptor antagonists